Full List Of Stories
Weeky review
The FTSE 100 finished the week almost flat, up 14. 02 points or 0. 19%, at 7,323. 98.
Acacia remains a 'buy' for HSBC but target price slashed
HSBC cut its target price for Acacia Mining by 47% but kept its 'buy' recommendation in place as the months-long spat with the Tanzanian government still hangs over the company.
AppScatter eyes IPO in early September
AppScatter Group, a mobile app distribution and management platform, is drumming up institutional investor support for a flotation on London's AIM market in early September.
London midday: FTSE flops as Trump-risk aversion hits global markets
London's FTSE 100 index fell below a key technical level as Friday's session wore on, with travel stocks leading the retreat after the terror attacks in Barcelona and the large cabal of overseas focused companies hit by the dollar's weakness amid renewed concerns about the US Presidency.
Spending at pubs and restaurants holds up despite consumer squeeze
Spending in at pubs and restaurants in July held firm at fairly subdued levels in July, according to new research published on Friday that indicates consumers are prioritising certain types of spending.
Airlines fly lower after Barcelona attack
Airline stocks took a nosedive on Friday morning as the horrific van attack in Barcelona the previous evening was felt likely to hit tourism to the region.
Undervalued Prudential could get huge upside from break-up - Credit Suisse
Prudential is already trading at a discount to the UK life insurance sector and, amid rumours of a potential break-up, Credit Suisse calculated there could be considerable upside from such a move.
London open: Stocks slide following Wall St wobble, airlines hit by Barcelona fears
London stocks nosedived in early trade on Friday, with airlines leading the retreat after the terror attacks in Barcelona and following steep losses overnight on Wall Street amid renewed concerns about the Presidency.
Astrazeneca wins wider US approval for Lynparza ovarian cancer drug
AstraZeneca and Merck have been given approval by the US drug administrator to sell their olaparib ovarian cancer drug, branded Lynparza, in a new tablet form and to a wider range of cancer sufferers.
Friday newspaper round-up: Brexit deals, White House, productivity, Cuadrilla
EU migrants will be barred from claiming in-work benefits unless they have been employed for at least four years after Brexit under plans to revive a pledge by David Cameron. Ministers are understood to be examining plans to bar migrants who arrive in the UK after March 2019 from claiming in-work benefits unless they have worked in the UK and "contributed" for four years. - The Telegraph.
CMA approves Heineken's Punch purchase if 33 pubs are sold
The UK competition regulator has approved the sale of a swathe of Punch Taverns' pubs to Heineken as long as the Dutch brewer sells .
Reckitt completes food sale, Astra cancer drug gets FDA win
London open The FTSE 100 was being called 43 points lower by traders in the City on Friday morning, having finished at 7,387. 87 the day before.